

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

PPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/994,068	11/27/2001	Tsutomu Arakawa	06843.0028-02000	8561
22852 75	590 06/17/2005	EXAMINER		
•	HENDERSON, FARAI	GODDARD, LAURA B		
LLP 901 NEW YORK AVENUE, NW WASHINGTON, DC 20001-4413			ART UNIT	PAPER NUMBER
			1642	

DATE MAILED: 06/17/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
Office Action Summary		09/994,068	ARAKAWA ET AL.				
		Examiner	Art Unit				
		Laura B. Goddard, Ph.D.	1642				
Period fo	The MAILING DATE of this communication apport Reply	pears on the cover sheet with the	correspondence address				
THE I - Exter after - If the - If NO - Failu Any r	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. Insions of time may be available under the provisions of 37 CFR 1.1 SIX (6) MONTHS from the mailing date of this communication. In period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period are to reply within the set or extended period for reply will, by statuted reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be to within the statutory minimum of thirty (30) dawill apply and will expire SIX (6) MONTHS from a cause the application to become ABANDON	imely filed ays will be considered timely. The mailing date of this communication. ED (35 U.S.C. § 133).				
Status							
1)🖂	Responsive to communication(s) filed on <u>09 A</u>	pril 2002.					
2a) <u></u> □	This action is FINAL . 2b)⊠ This	action is non-final.					
3)	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
	closed in accordance with the practice under E	Ex parte Quayle, 1935 C.D. 11, 4	153 O.G. 213.				
Dispositi	on of Claims						
4)🖂	4)⊠ Claim(s) <u>1-56</u> is/are pending in the application.						
	4a) Of the above claim(s) is/are withdrawn from consideration.						
5)□) ☐ Claim(s) is/are allowed.						
6)□	Claim(s) is/are rejected.						
• ——	Claim(s) is/are objected to.						
8)🖾	Claim(s) <u>1-56</u> are subject to restriction and/or	election requirement.					
Applicati	ion Papers						
9)	The specification is objected to by the Examine	er.	•				
10)	10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11)	The oath or declaration is objected to by the Ex	xaminer. Note the attached Offic	e Action or form PTO-152.				
Priority (ınder 35 U.S.C. § 119						
12)	Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. § 119(a	a)-(d) or (f).				
a) ☐ All b) ☐ Some * c) ☐ None of:							
	1. Certified copies of the priority document	ts have been received.					
	2. Certified copies of the priority document	ts have been received in Applica	ition No				
	3. Copies of the certified copies of the prior	rity documents have been receive	ved in this National Stage				
	application from the International Burea						
* See the attached detailed Office action for a list of the certified copies not received.							
			•				
Attachment(s) A							
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 4) Interview Summary (PTO-413) Paper No(s)/Mail Date							
3) Infor	mation Disclosure Statement(s) (PTO-1449 or PTO/SB/08)	, · · · · · · · · · · · · · · · · · · ·	Patent Application (PTO-152)				
Раре	er No(s)/Mail Date	6)					

Art Unit: 1642

رنز

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

Claim 19 links Groups I-III. The restriction requirement among the linked inventions is subject to the nonallowance of the linking claim(s), claim 19. Upon the allowance of the linking claim(s), the restriction requirement as to the linked inventions shall be withdrawn and any claim(s) depending from or otherwise including all the limitations of the allowable linking claim(s) will be entitled to examination in the instant application. Applicant(s) are advised that if any such claim(s) depending from or including all the limitations of the allowable linking claim(s) is/are presented in a continuation or divisional application, the claims of the continuation or divisional application may be subject to provisional statutory and/ or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. *In re Ziegler*, 44 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

1. Claims 19-28, 33-41, and 46 drawn to a method of treating cancer with an antibody, classified in class 514, subclass 2.

Art Unit: 1642

- II. Claims 19, 29-30, and 42-43, drawn to a method of treating cancer with an antibody in combination with a chemotherapeutic agent, classified in class 514, subclass 2.
- III. Claims 19, 31-32, and 44-45, drawn to a method of treating cancer with an antibody conjugated to a cytotoxic agent classified in class 514, subclass 2.
- IV. Claims 47-56, drawn to a method for inducing apoptosis comprising administering an antibody or fragment thereof, classified in class 435, subclass 4.

The inventions are distinct, each from the other because of the following reasons:

The inventions of Groups I-IV are materially distinct methods which differ at least in objectives, method steps and reagents. For example, Groups I – III are drawn to a method of treating cancer but each Group differs in the reagents and steps they use to treat the cancer: an antibody (I), an antibody with a chemotherapeutic agent (II), and an antibody conjugated to a cytotoxic agent (III). Group IV is drawn to a method with an objective differing from Groups I-III: inducing apoptosis by administering an antibody. Each of the groups employs chemically distinct reagents to accomplish the various

Art Unit: 1642

objectives. Searching all of the groups with all of the different reagents, steps or objectives would invoke a high burden of search.

Because these inventions are distinct for the reasons given above and the search required for one Group is not required for any other Group, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Laura B. Goddard, Ph.D. whose telephone number is (571) 272-8788. The examiner can normally be reached on 8:00am-5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Siew can be reached on 571-272-0787. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1642

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Laura B Goddard, Ph.D. Examiner
Art Unit 1642

SUSAN UNGAR, PH.D PRIMARY EXAMINER